These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 18279452

  • 1. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
    Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stöhr T, Andersson KE.
    BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
    McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS.
    Eur J Pharmacol; 2009 Mar 01; 605(1-3):145-52. PubMed ID: 19168050
    [Abstract] [Full Text] [Related]

  • 3. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo.
    Hegde SS, Choppin A, Bonhaus D, Briaud S, Loeb M, Moy TM, Loury D, Eglen RM.
    Br J Pharmacol; 1997 Apr 01; 120(8):1409-18. PubMed ID: 9113359
    [Abstract] [Full Text] [Related]

  • 4. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
    Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB.
    Urology; 2005 Feb 01; 65(2):238-42. PubMed ID: 15708029
    [Abstract] [Full Text] [Related]

  • 5. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
    Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E.
    J Pharmacol Exp Ther; 2009 Mar 01; 328(3):893-9. PubMed ID: 19029429
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
    Ohtake A, Saitoh C, Yuyama H, Ukai M, Okutsu H, Noguchi Y, Hatanaka T, Suzuki M, Sato S, Sasamata M, Miyata K.
    Biol Pharm Bull; 2007 Jan 01; 30(1):54-8. PubMed ID: 17202659
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
    Ohtake A, Ukai M, Hatanaka T, Kobayashi S, Ikeda K, Sato S, Miyata K, Sasamata M.
    Eur J Pharmacol; 2004 May 25; 492(2-3):243-50. PubMed ID: 15178371
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological effects of solifenacin on human isolated urinary bladder.
    Masunaga K, Yoshida M, Inadome A, Murakami S, Sugiyama Y, Satoji Y, Maeda Y, Ueda S.
    Pharmacology; 2008 May 25; 82(1):43-52. PubMed ID: 18434763
    [Abstract] [Full Text] [Related]

  • 9. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
    Yusup A, Akino H, Miwa Y, Oyama N, Aoki Y, Ito H, Tanase K, Matsuta Y, Nakai M, Yokoyama O.
    Eur J Pharmacol; 2007 Dec 22; 577(1-3):143-9. PubMed ID: 17904547
    [Abstract] [Full Text] [Related]

  • 10. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
    Kaiho Y, Nishiguchi J, Kwon DD, Chancellor MB, Arai Y, Snyder PB, Yoshimura N.
    BJU Int; 2008 Mar 22; 101(5):615-20. PubMed ID: 18070178
    [Abstract] [Full Text] [Related]

  • 11. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.
    Nelson CP, Gupta P, Napier CM, Nahorski SR, Challiss RA.
    J Pharmacol Exp Ther; 2004 Sep 22; 310(3):1255-65. PubMed ID: 15140916
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
    Hirose H, Aoki I, Kimura T, Fujikawa T, Numazawa T, Sasaki K, Sato A, Hasegawa T, Nishikibe M, Mitsuya M, Ohtake N, Mase T, Noguchi K.
    J Pharmacol Exp Ther; 2001 May 22; 297(2):790-7. PubMed ID: 11303071
    [Abstract] [Full Text] [Related]

  • 13. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T, Maruyama S, Takagi Y, Yamamura HI, Yamada S.
    Eur J Pharmacol; 2006 Jan 04; 529(1-3):157-63. PubMed ID: 16316647
    [Abstract] [Full Text] [Related]

  • 14. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
    Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S.
    J Urol; 2006 Jan 04; 175(1):365-9. PubMed ID: 16406943
    [Abstract] [Full Text] [Related]

  • 15. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction.
    Füllhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson KE.
    BJU Int; 2010 Jul 04; 106(2):287-93. PubMed ID: 19888972
    [Abstract] [Full Text] [Related]

  • 16. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
    Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug 04; 366(2):97-103. PubMed ID: 12122494
    [Abstract] [Full Text] [Related]

  • 17. Tolterodine--a new bladder-selective antimuscarinic agent.
    Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B.
    Eur J Pharmacol; 1997 May 30; 327(2-3):195-207. PubMed ID: 9200560
    [Abstract] [Full Text] [Related]

  • 18. Muscarinic receptor function, density and G-protein coupling in the overactive diabetic rat bladder.
    Stevens LA, Sellers DJ, McKay NG, Chapple CR, Chess-Williams R.
    Auton Autacoid Pharmacol; 2006 Jul 30; 26(3):303-9. PubMed ID: 16879496
    [Abstract] [Full Text] [Related]

  • 19. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
    Yoshida A, Maruyama S, Fukumoto D, Tsukada H, Ito Y, Yamada S.
    Life Sci; 2010 Jul 31; 87(5-6):175-80. PubMed ID: 20598326
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory mechanism of BRL37344 on muscarinic receptor-mediated contractions of the rat urinary bladder smooth muscle.
    Kubota Y, Nakahara T, Yunoki M, Mitani A, Maruko T, Sakamoto K, Ishii K.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep 31; 366(3):198-203. PubMed ID: 12172701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.